H<sub>1</sub> receptor | Histamine receptors | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲

H1 receptor

target has curated data in GtoImmuPdb

Target id: 262

Nomenclature: H1 receptor

Family: Histamine receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 487 3p25 HRH1 histamine receptor H1 17-18,26,49,69
Mouse 7 488 6 E3 Hrh1 histamine receptor H1 38
Rat 7 486 4q42 Hrh1 histamine receptor H 1 24
Previous and Unofficial Names
H1R | HH1R | Hisr
Database Links
Specialist databases
GPCRDB hrh1_human (Hs), hrh1_mouse (Mm), hrh1_rat (Rn)
Other databases
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Histamine H1 receptor in complex with antagonist
PDB Id:  3RZE
Ligand:  doxepin
Resolution:  3.1Å
Species:  Human
References:  84
Natural/Endogenous Ligands
histamine

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Parameter Reference
dimethylhistaprodifen Hs Full agonist 6.4 pKi 83
pKi 6.4 [83]
methylhistaprodifen Hs Full agonist 6.4 pKi 83
pKi 6.4 (Ki 3.98x10-7 M) [83]
ST-1006 Hs Agonist <6.0 pKi 76
pKi <6.0 (Ki >1x10-6 M) [76]
2-(3-iodophenyl)histamine Hs Full agonist 5.8 pKi 83
pKi 5.8 [83]
2-(3-bromophenyl)histamine Hs Full agonist 5.7 pKi 83
pKi 5.7 [83]
2-(3-chlorophenyl)histamine Hs Full agonist 5.7 pKi 83
pKi 5.7 [83]
histaprodifen Hs Full agonist 5.7 pKi 52
pKi 5.7 [52]
2-(2-thiazolyl)ethanamine Hs Partial agonist 5.3 pKi 83
pKi 5.3 [83]
histamine Hs Full agonist 4.7 – 5.9 pKi 8,69,79,83,92
pKi 4.7 – 5.9 [8,69,79,83,92]
UR-PG55B Hs Full agonist 5.2 pKi 92
pKi 5.2 [92]
UR-PG131A Hs Full agonist 4.7 pKi 92
pKi 4.7 [92]
UR-PG153 Hs Full agonist 4.7 pKi 92
pKi 4.7 [92]
oxo-arpromidine Hs Full agonist 4.5 pKi 92
pKi 4.5 [92]
UR-PG146 Hs Full agonist 4.4 pKi 92
pKi 4.4 [92]
2-pyridylethylamine Hs Full agonist 3.7 pKi 79
pKi 3.7 [79]
vilazodone Hs Agonist 6.5 pIC50 34
pIC50 6.5 (IC50 3.17x10-7 M) [34]
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Parameter Reference
[11C]doxepin Hs Antagonist 9.0 pKd 40
pKd 9.0 (Kd 1x10-9 M) [40]
[3H]pyrilamine Hs Inverse agonist 8.4 – 9.1 pKd 18,69,82-83
pKd 8.4 – 9.1 (Kd 4x10-9 – 7.9x10-10 M) [18,69,82-83]
tripelennamine Hs Antagonist 8.0 pKd 33
pKd 8.0 (Kd 1x10-8 M) [33]
clemastine Hs Antagonist 10.3 pKi 3
pKi 10.3 (Ki 4.9x10-11 M) [3]
cyproheptadine Hs Antagonist 10.2 pKi 69
pKi 10.2 [69]
asenapine Hs Antagonist 9.8 pKi 82
pKi 9.8 [82]
doxepin Hs Antagonist 9.5 – 10.0 pKi 8
pKi 9.5 – 10.0 [8]
promethazine Hs Antagonist 9.6 pKi 28
pKi 9.6 (Ki 2.4x10-10 M) [28]
amitriptyline Hs Antagonist 9.3 pKi 28
pKi 9.3 (Ki 5x10-10 M) [28]
Description: Antagonism of [3H]mepyramine binding
clozapine Hs Antagonist 8.8 – 9.6 pKi 8,46,82
pKi 8.8 – 9.6 [8,46,82]
zotepine Hs Antagonist 9.2 pKi 82
pKi 9.2 [82]
alimemazine Bt Antagonist 9.1 pKi 47
pKi 9.1 (Ki 7.2x10-10 M) [47]
Description: Inhibition of [3H]mepyramine binding to bovine brain membrane preparations in vitro.
desloratadine Hs Antagonist 9.0 pKi 50
pKi 9.0 (Ki 9.7x10-10 M) [50]
olanzapine Hs Antagonist 8.7 – 9.2 pKi 46,82
pKi 8.7 – 9.2 [46,82]
azelastine Hs Antagonist 8.9 pKi 78
pKi 8.9 (Ki 1.26x10-9 M) [78]
mepyramine Hs Inverse agonist 8.7 – 9.0 pKi 8,79
pKi 8.7 – 9.0 [8,79]
triprolidine Hs Antagonist 8.5 – 9.0 pKi 8,69
pKi 8.5 – 9.0 (Ki 3.16x10-9 – 1x10-9 M) [8,69]
(-)-trans-H2-PAT Hs Antagonist 8.6 – 8.8 pKi 8
pKi 8.6 – 8.8 [8]
hydroxyzine Hs Antagonist 8.7 pKi 30
pKi 8.7 (Ki 1.99x10-9 M) [30]
ketotifen Hs Antagonist 8.6 pKi 48
pKi 8.6 (Ki 2.5x10-9 M) [48]
mizolastine Hs Antagonist 8.6 pKi 13
pKi 8.6 (Ki 2.7x10-9 M) [13]
Description: Radioligand displacement membrane binding assay using CHO cells expressing the human H1 receptor and [3H]pyrilamine as tracer.
astemizole Hs Antagonist 8.5 pKi 77
pKi 8.5 (Ki 3x10-9 M) [77]
(±)-trans-H2-PAT Hs Antagonist 8.4 – 8.6 pKi 8
pKi 8.4 – 8.6 [8]
(R)-cetirizine Hs Inverse agonist 8.5 pKi 79
pKi 8.5 [79]
(+)-chlorpheniramine Hs Antagonist 8.3 – 8.6 pKi 8,69
pKi 8.3 – 8.6 [8,69]
thiothixene Hs Antagonist 8.4 pKi 46
pKi 8.4 [46]
dosulepin Hs Antagonist 8.4 pKi 86
pKi 8.4 (Ki 4x10-9 M) [86]
quetiapine Hs Antagonist 8.0 – 8.7 pKi 46,82
pKi 8.0 – 8.7 [46,82]
cyclizine Hs Antagonist 8.4 pKi 3
pKi 8.4 (Ki 4.44x10-9 M) [3]
chlorpromazine Hs Antagonist 8.2 pKi 46
pKi 8.2 [46]
loxapine Hs Antagonist 8.2 pKi 46
pKi 8.2 [46]
cetirizine Hs Inverse agonist 8.2 pKi 69
pKi 8.2 [69]
chlorpheniramine Hs Antagonist 8.1 pKi 78
pKi 8.1 (Ki 7x10-9 M) [78]
perphenazine Hs Antagonist 8.1 pKi 46
pKi 8.1 [46]
(±)-cis-H2-PAT Hs Antagonist 7.8 – 8.2 pKi 8
pKi 8.1 – 8.2 [8]
pKi 7.8 – 7.9 [8]
fluspirilene Hs Antagonist 7.9 pKi 82
pKi 7.9 [82]
diphenhydramine Hs Antagonist 7.9 pKi 8
pKi 7.9 [8]
risperidone Hs Antagonist 7.6 – 7.8 pKi 46,82
pKi 7.6 – 7.8 [46,82]
thioridazine Hs Antagonist 7.7 pKi 46
pKi 7.7 [46]
fluphenazine Hs Antagonist 7.7 pKi 46
pKi 7.7 [46]
ziprasidone Hs Antagonist 7.4 – 7.8 pKi 46,82
pKi 7.4 – 7.8 [46,82]
fexofenadine Hs Antagonist 7.6 pKi 2
pKi 7.6 (Ki 2.7x10-8 M) [2]
aripiprazole Hs Antagonist 7.5 pKi 46
pKi 7.5 [46]
9-OH-risperidone Hs Antagonist 7.5 pKi 82
pKi 7.5 [82]
AZD3778 Hs Antagonist 7.5 pKi 5
pKi 7.5 (Ki 3.16x10-8 M) [5]
Description: Assayed using the sodium salt of the compound
(+)-trans-H2-PAT Hs Antagonist 7.4 – 7.5 pKi 8
pKi 7.4 – 7.5 [8]
loratadine Hs Antagonist 7.4 pKi 43
pKi 7.4 (Ki 3.7x10-8 M) [43]
terfenadine Hs Antagonist 7.4 pKi 2
pKi 7.4 (Ki 4x10-8 M) [2]
trifluoperazine Hs Antagonist 7.2 pKi 46
pKi 7.2 [46]
(S)-dimetindene Hs Antagonist 7.2 pKi 11
pKi 7.2 (Ki 6.9x10-8 M) [11]
rupatadine Cp Antagonist 7.0 pKi 63
pKi 7.0 (Ki 1x10-7 M) [63]
Description: [3H]-pyrilamine binding to guinea pig cerebellum membranes.
sertindole Hs Antagonist 6.9 pKi 46,82
pKi 6.9 [46,82]
(+)-cis-H2-PAT Hs Antagonist 6.9 pKi 8
pKi 6.9 [8]
(S)-cetirizine Hs Inverse agonist 6.7 pKi 79
pKi 6.7 [79]
BU-E 47 Hs Antagonist 6.6 pKi 83
pKi 6.6 [83]
(-)-chlorpheniramine Hs Antagonist 6.4 – 6.7 pKi 8
pKi 6.4 – 6.7 [8]
arpromidine Hs Antagonist 6.5 pKi 83,92
pKi 6.5 [83,92]
pimozide Hs Antagonist 6.2 pKi 46
pKi 6.2 [46]
JNJ-39758979 Hs Antagonist <6.0 pKi 76
pKi <6.0 (Ki >1x10-6 M) [76]
haloperidol Hs Antagonist 5.7 – 6.1 pKi 46,82
pKi 5.7 – 6.1 [46,82]
ABT-239 Hs Inverse agonist 5.8 pKi 22
pKi 5.8 [22]
pitolisant Hs Antagonist 5.8 pKi 76
pKi 5.8 [76]
molindone Hs Antagonist 5.7 pKi 46
pKi 5.7 [46]
pipamperone Hs Antagonist 5.6 pKi 82
pKi 5.6 [82]
A-349821 Hs Inverse agonist 5.6 pKi 21
pKi 5.6 [21]
clobenpropit Hs Antagonist 5.6 pKi 23
pKi 5.6 [23]
A-317920 Hs Antagonist 5.4 pKi 21,23
pKi 5.4 [21,23]
impromidine Hs Antagonist 5.2 pKi 92
pKi 5.2 [92]
ciproxifan Hs Antagonist <5.0 pKi 76
pKi <5.0 (Ki >1x10-5 M) [76]
MK-0249 Hs Antagonist <5.0 pKi 76
pKi <5.0 (Ki >1x10-5 M) [76]
conessine Hs Antagonist <5.0 pKi 76
pKi <5.0 (Ki >1x10-5 M) [76]
INCB-38579 Hs Antagonist <5.0 pKi 76
pKi <5.0 (Ki >1x10-5 M) [76]
rupatadine Hs Antagonist 8.4 pIC50 72
pIC50 8.4 (IC50 3.9x10-9 M) [72]
epinastine Hs Antagonist 7.6 pIC50 36
pIC50 7.6 (IC50 2.5x10-8 M) [36]
Description: Antagonism of 5 nM [3H]mepyramine binding in an intact cell assay using U373 MG astrocytoma cells.
tripelennamine Hs Antagonist 7.4 pIC50 33
pIC50 7.4 (IC50 3.98x10-8 M) [33]
mizolastine Cp Antagonist 7.3 pIC50 6
pIC50 7.3 (IC50 4.7x10-8 M) [6]
Description: Inhibition of [3H]pyrilamine binding to histamine H1 receptors in guinea pig cerebellar membranes and sections.
[11C]pyrilamine Hs Inverse agonist - -
View species-specific antagonist tables
Antagonist Comments
Astemizole is highly selective for the histamine H1 receptor over the H2 receptor.
Immunopharmacology Comments
The H1 receptor was the first of the family to be targeted for clinical use, with antagonists (anti-histamines) developed that are still used widely to treat allergic inflammation such as rhinitis, allergic conjunctivitis, urticaria and even anaphylaxis.
Cell Type Associations
Immuno Cell Type:  Granulocytes
Cell Ontology Term:   eosinophil (CL:0000771)
Comment:  Eosinophils express all four histamine receptor subtypes.
References:  29,64
Immuno Cell Type:  Mast cells
Cell Ontology Term:   mast cell (CL:0000097)
Comment:  In humans, mast cells express H1R, H2R and H4R.
References:  27
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 2 GO processes
GO:0006954 inflammatory response TAS
click arrow to show/hide IEA associations
GO:0048245 eosinophil chemotaxis IEA
Immuno Process:  Chemotaxis & migration
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0048245 eosinophil chemotaxis IEA
Primary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Adenylate cyclase stimulation
Comments:  Stimulation of cAMP accumulation is via Gβγ subunits of Gq [58].
References:  58
Secondary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
References:  51
Tissue Distribution
Brain: cerebrum.
Heart: myocardium (ventricle > atrium).
Species:  Human
Technique:  Northern and Western blotting.
References:  62
Brain.
Species:  Human
Technique:  Positron emission tomography (PET).
References:  68
Cranial arteries.
Species:  Human
Technique:  RT-PCR.
References:  42
Myometrium.
Species:  Human
Technique:  Radioligand binding.
References:  31
Gastrointestinal tract.
Species:  Human
Technique:  qRT-PCR and immunohistochemistry.
References:  80
Uterine horns.
Species:  Mouse
Technique:  Radioligand binding.
References:  32
Mast cells.
Species:  Mouse
Technique:  RT-PCR.
References:  37
Sympathetic preganglionic neurons in the spinal cord.
Species:  Rat
Technique:  RT-PCR.
References:  90
Embryonic brain and spinal cord.
Species:  Rat
Technique:  in situ hybridization, RT-PCR and Northern blotting.
References:  45
Brain: cerebrum.
Heart: myocardium (atrium and ventricle).
Species:  Rat
Technique:  Northern and Western blotting.
References:  62
Cochlea.
Species:  Rat
Technique:  RT-PCR.
References:  4
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of cAMP levels in CHO cells transfected with the human H1 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of cAMP accumulation.
References:  58
Measurement of IP levels in COS-7 cells transfected with the human H1 receptor.
Species:  Human
Tissue:  COS-7 cells.
Response measured:  Stimulation of IP formation.
References:  17
Measurement of IP levels in CHO cells transfected with the human H1 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of IP formation.
References:  8
Measurement of AC activity in baculovirus-infected Sf9 insect cells expressing the human H1 receptor.
Species:  Human
Tissue:  Sf9 cells.
Response measured:  Stimulation of AC activity.
References:  92
Measurement of PLC activity and Ca2+ mobilisation in cultured ciliary muscle cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Cultured ciliary muscle cells.
Response measured:  Activation of PLC and mobilisation of both intracellular and extracellular Ca2+.
References:  56
Measurement of IP levels in cultured human endothelial cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Cultured umbilical vein endothelial cells.
Response measured:  Stimulation of IP formation.
References:  53
Measurement of mitogenesis in human astrocytoma U373 MG cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Astrocytoma U373 MG cells.
Response measured:  Cell proliferation via PKC and MAPK.
References:  35
Measurement of Ca2+ levels as well as ERK1/2 and PKC activity in human primary epithelial cells and the NCI-H292 cell line, both endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Primary epithelial cells and the NCI-H292 cell line.
Response measured:  Elevation of Ca2+ levels and activation of PKC and ERK1/2.
References:  61
Measurement of IP, DAG and Ca2+ levels in human HeLa carcinoma cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  HeLa carcinoma cells.
Response measured:  Formation of IP and DAG and a rise in Ca2+ levels.
References:  88
Physiological Functions
Contraction of smooth muscle.
Species:  Rat
Tissue:  Isolated stomach fundus.
References:  20
Inhibition of locomotor behaviour.
Species:  Rat
Tissue:  In vivo.
References:  1
Relaxation of smooth muscle (via an endothelial H1 receptor).
Species:  Human
Tissue:  Cranial arteries.
References:  42
Contraction of smooth muscle.
Species:  Human
Tissue:  Arterial rings.
References:  16
Modulation of adrenergic neurotransmission.
Species:  Rat
Tissue:  Vas deferens.
References:  89
Bronchoconstriction.
Species:  Human
Tissue:  In vivo.
References:  12,14,19,54,73,87
Modulation of feeding behaviour.
Species:  Rat
Tissue:  In vivo.
References:  25
Modulation of feeding behaviour.
Species:  Mouse
Tissue:  In vivo.
References:  59-60,70-71
Hypernociception.
Species:  Rat
Tissue:  In vivo.
References:  55
Endothelium-dependent vasodilation.
Species:  Rat
Tissue:  Mesenteric vascular beds.
References:  44
Role in the stimulation of skin blood flow during whole body heating.
Species:  Human
Tissue:  In vivo.
References:  91
Stimulation of the nitric oxide signalling system.
Species:  Rat
Tissue:  Submandibular gland.
References:  9
Increased vascular permeability.
Species:  Mouse
Tissue:  In vivo.
References:  7,74
Modulation of neuronal firing.
Species:  Rat
Tissue:  Dorsal raphe nucleus.
References:  10
Contraction of smooth muscle.
Species:  Human
Tissue:  Isolated uterine strips.
References:  57
Increase in substantia nigra pars reticulata (SNr) inhibitory projection neuron firing frequency (via cell depolarisation).
The balance between the effect of H1 and H2 receptors and the opposing effect of H3 receptors may contribute to movement control.
Species:  Mouse
Tissue:  Coronal midbrain slices.
References:  95
Depolarisation.
Species:  Rat
Tissue:  Sympathetic preganglionic neurons.
References:  90
Regulation of cytokine production.
Species:  Mouse
Tissue:  CD4+ and CD8+ T cells.
References:  85
Prostacyclin formation.
Species:  Human
Tissue:  Pulmonary artery.
References:  81
Physiological Consequences of Altering Gene Expression
H1 receptor knockout mice exhibit a reduction in the effect of neurotensin on the supression of food intake.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  75
H1 receptor knockout mice develop normally, but exhibit impaired locomotor activity and exploratory behavior.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  39,94
H1 receptor knockout mice subjected to social isolation after weaning exhibit similar levels of locomotor activity to socially reared H1 receptor knockout mice. This is in contrast to wild-type mice, where there is a significant decrease in locomotor activity in socially isolated WT mice compared with socially reared WT mice. It is suggested that blockade of H1 receptors by atypical antipsychotics attenuates social isolation-induced behavioral changes.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  15
H1 receptor knockout mice exhibit decreased exploratory activity, reduced levels of anxiety and aggression, a decrease in nociceptive response and an increased 5-HT turnover rate in the cerebral cortex and hippocampus.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  93
H1 receptor knockout mice exhibit a significant decrease in nociception compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  66
H1 knockout mice exhibit enhancement of morphine-induced antinociception.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  65
H1 receptor knockout mice do not exhibit an increase in respiratory frequency upon elevation of body temperature, as observed in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  41
H1 receptor knockout mice do not exhibit an increase in vascular permeability of the conjunctiva, as observed in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  74
CD4+ T cells from H1 receptor knockout mice exhibit a decrease in the release of Il-2 and Il-10, and an increase in the release of IL-4. CD8+ T cells from H1 receptor knockout mice also exhibit a decrease in the release of Il-2 and Il-10, as well as an increase in the release of IFN-γ.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  85
H1 receptor knockout mice exhibit enhanced antinociception by administration of orexin-A, compared to wild-type mice following administration of orexin-A.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  67
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0004924 abnormal behavior PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0001502 abnormal circadian rhythm PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0005093 decreased B cell proliferation PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0001262 decreased body weight PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0002727 decreased circulating insulin level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0003910 decreased eating behavior PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0001417 decreased exploration in new environment PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0008498 decreased IgG3 level PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0001806 decreased IgM level PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0001876 decreased inflammatory response PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0008567 decreased interferon-gamma secretion PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0008567 decreased interferon-gamma secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0008673 decreased interleukin-13 secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0008688 decreased interleukin-2 secretion PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0008703 decreased interleukin-5 secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0005018 decreased T cell number PMID: